Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Epimmune and IDM to merge
The two companies have signed a definitive agreement under which Epimmune will combine with privately-held IDM in an all-stock transaction. By combining, Epimmune and IDM expect to create
The two companies have signed a definitive agreement under which Epimmune will combine with privately-held IDM in an all-stock transaction. By combining, Epimmune and IDM expect to create
The milestone payment comes as a result of a collaboration agreement between Icagen and Yamanouchi in dementia, including Alzheimer’s disease, which began in 2000. “A variety of ion
The clinical trial has been designed to provide further evidence that inhibiting overproduction of TNF-alpha, and other cytokines, may provide a therapeutic benefit to those suffering from AIDS.
GlaxoSmithKline’s booster vaccine candidate, Boostrix, received a unanimous favorable recommendation from the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC). If approved, Boostrix would add a pertussis
The official approval marks a significant milestone in the growth of Sinovac’s inactivated vaccines portfolio and comes as the company is nearing completion of its new production line
Accelerated approval and priority review are specific regulatory programs developed by the FDA to expedite the availability of products addressing important needs. ID Biomedical and the FDA’s Center
Under the terms of the Genzyme collaboration, over the next 18 months, Genzyme will conduct research to improve production and characterization of islet stem cells, and undertake preclinical
Designation as an orphan drug, which is intended to facilitate product development, provides eligibility for a seven-year period of market exclusivity after approval, grants and tax credits for
In the exploratory clinical trial, Miraxion was used as adjunct therapy, with either selective serotonin reuptake inhibitors or tricyclics, in 115 patients with treatment-unresponsive depression. Although in the
This new compound, QRX-431, which QuatRx licensed from EndoChem, is designed to treat lipid abnormalities involving LDL-cholesterol and Lp(a), both recognized as risk factors for cardiovascular disease. The